PHASE II STUDY PS341 ALONE OR COMB W/ IRINOTECAN IN PATIENTS W/ ADENOCARCINOMA

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Aims are: (1) to determine response rate for combination of irinotecan and PS341 in patients with previously untreated adenocarcinoma of gastroesophageal juntion or stomach; (2) to determine response rate for PS341 in patients with previously treated adenocarcinoma of the gastrophageal junction or stomach, the toxicities and recovery from toxicities for patients recieving PS341 alone or in combincation with irinotecan; and (3) to perform GeneChip analysis on biopsy specimens prior to and subsequent to treatment with PS341 to determine changes in patterns of gene espression.